Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family that interacts with several receptors, including TRAIL-R1, TRAIL-R2, and TRAIL-R4. TRAIL-R1 and TRAIL-R2 can induce apoptosis of cancer cells and activate the transcription factor NF-B. TRAIL-R4 can activate NF-B and protect cells from TRAIL-induced apoptosis. Here we show that TRAIL-R1-, TRAIL-R2-, and TRAIL-R4-induced NF-B activation are mediated by a TRAF2-NIK-IB kinase ␣/␤ signaling cascade but is MEKK1 independent. TRAIL receptors also activate the protein kinase JNK. JNK activation by TRAIL-R1 is mediated by a TRAF2-MEKK1-MKK4 but not the TRAF2-NIK/IB kinase ␣/␤ signaling pathway. We also show that activation of NF-B or overexpression of TRAIL-R4 does not protect TRAIL-R1-induced apoptosis. Moreover, inhibition of NF-B by IB␣ sensitizes cells to tumor necrosis factor-but not TRAIL-induced apoptosis. These findings suggest that TRAIL receptors induce apoptosis, NF-B and JNK activation through distinct signaling pathways, and activation of NF-B is not sufficient for protecting cells from TRAIL-induced apoptosis.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is
Tumor necrosis factor (TNF) 1 -related apoptosis-inducing ligand (TRAIL) is a member of the TNF family, which also includes TNF and FasL (1) (2) (3) . Unlike TNF and FasL, which are mainly expressed by activated immune cells, TRAIL is constitutively expressed in most normal tissues (4, 5) . Previous studies suggest that TRAIL is capable of inducing apoptosis of various cancer cell lines but not of normal cells (3) (4) (5) , pointing to the possibility of developing TRAIL as a reagent for cancer treatment.
TRAIL induces apoptosis through two receptors, TRAIL-R1(DR4) (3, 6) and TRAIL-R2(DR5) (7) (8) (9) (10) (11) (12) . Both TRAIL-R1 and TRAIL-R2 contain a conserved cytoplasmic region called "death domain" that is required for TRAIL-R1-and TRAIL-R2-induced apoptosis. Three additional receptors, TRAIL-R3(TRID/DcR1/LIT) (7, 10, 13, 14) , TRAIL-R4 (15, 16) , and osteoprotegerin (17) , also bind to TRAIL. TRAIL-R3 does not have a cytoplasmic domain and can protect cells from TRAILinduced apoptosis, probably by functioning as a "decoy" receptor (7, 10) . TRAIL-R4 retains a cytoplasmic fragment containing one-third of the consensus death domain motif. Overexpression of TRAIL-R4 activates the transcription factor NF-B and protects cells against TRAIL-induced apoptosis, suggesting that TRAIL-R4, unlike TRAIL-R3, has a functional intracellular signaling domain (15, 16) . Thus, TRAIL-R4 may protect cells from TRAIL-induced apoptosis by either acting as a decoy receptor or transducing an anti-apoptotic signal. In this context, several studies have established that NF-B activation can protect cells from TNF-induced apoptosis, probably through its ability to induce the expression of anti-apoptosis genes (18 -20) . In addition to TRAIL-R4, it has been shown recently that TRAIL-R1 and TRAIL-R2 can also activate NF-B (8, 10, 21) . These observations suggest that activation of NF-B alone is not sufficient to block apoptosis induced by TRAIL receptors.
Currently, the intracellular signaling pathways responsible for TRAIL receptor-mediated NF-B activation are unclear, and the mechanisms responsible for TRAIL receptor-induced apoptosis are controversial. It has been reported that TRADD and FADD, two death domain-containing cytoplasmic proteins involved in TNF-R1 signaling, interact with TRAIL-R1 and TRAIL-R2 and are involved in apoptosis mediated by these receptors (8, 21) . However, other studies have reached opposite conclusions (6, 7, 10) . Moreover, studies using FADD knockout embryonic fibroblasts suggest that FADD is not required for apoptosis induced by overexpression of TRAIL-R1 (22) .
The signaling pathways mediated by TNF receptor family members have been best illustrated by studies with TNF-R1. TNF-R1 is a death domain-containing receptor that can induce apoptosis and activate NF-B and JNK kinase (23) (24) (25) (26) . The death domain of TNF-R1 interacts with TRADD in a TNF-dependent process (24, 25, 27) . Once TRADD is recruited to TNF-R1, it functions as an adapter protein to recruit several structurally and functionally divergent proteins, including FADD, RIP, TRAF2, and cIAP1 (25, 27, 28) . The interaction of TRADD with FADD leads to apoptosis through the activation of a caspase cascade (24) . The interaction of TRADD with TRAF2 and RIP activates NIK, a member of the mitogenactivated protein kinase kinase kinase family (29) . Once NIK is activated, it further activates two downstream kinases, IKK␣ and IKK␤ (29 -34) . It has been shown that IKK␣ and IKK␤ form a heterodimer complex that directly phosphorylates IBs (29 -35) . Once IBs are phosphorylated, they are degraded, and consequently the active NF-B is released (36, 37).
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In addition to NIK, TRAF2 and RIP can also activate MEKK1, another member of the mitogen-activated protein kinase kinase kinase family (26) . Although it has been suggested that overexpression of MEKK1 activates NF-B (38), it is believed that under physiological conditions, MEKK1 mediates TNF-R1-induced JNK but not NF-B activation (35) .
In this study, we investigated the mechanism of downstream signaling by TRAIL receptors. The results indicate that TRAIL-R1-, TRAIL-R2-, and TRAIL-R4-induced NF-B activation are mediated by a TRAF2-NIK-IKK␣/␤-dependent signaling cascade, whereas TRAIL-R1-induced JNK activation is mediated by a TRAF2-MEKK1-MKK4 dependent signaling cascade. We also show that inhibition of TRAIL-R1-induced NF-B and JNK activation pathways does not block TRAIL-R1-induced apoptosis. In addition, our data indicate that NF-B activation is not sufficient for protecting cells from TRAIL-induced apoptosis. TRAIL-R4 expression vector was constructed by replacing the TRAIL-R1 cDNA in the pCMV1-Flag-DR4 (TRAIL-R1) vector (6) with a polymerase chain reaction product of TRAIL-R4 cDNA. The parent vector contains a DNA fragment encoding a signal peptide at 5Ј of the Flag tag, and therefore the DNA fragment encoding the native Nterminal signal peptide of TRAIL-R4 was omitted by polymerase chain reaction.
Cell Transfection and Reporter Gene Assays-The human embryonic kidney 293 cell line was maintained in high glucose Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 100 g/ml penicillin G, and 100 g/ml streptomycin (Life Technologies, Inc.). For reporter gene assays, ϳ2 ϫ 10 5 cells/well were seeded on 6-well (35 mm) dishes. Cells were transfected the following day by the standard calcium phosphate precipitation method (39) . Luciferase reporter assays were performed using a luciferase assay kit (Pharmingen) following the manufacture's protocols.
Western Blotting-Western blots for detection of Flag-tagged TRAIL-R1, TRAIL-R2, and TRAIL-R4 were performed with a monoclonal antiFlag following previously described procedure (27, 40) .
Yeast Two-hybrid Screenings-The cDNA encoding the intracellular domain of TRAIL-R1 was inserted in frame into the Gal4 DNA-binding domain vector pGBT9 (CLONTECH). The human leukocyte, spleen, and 293 cell two-hybrid cDNA libraries were also from CLONTECH. The isolation of positive clones and subsequent two-hybrid interaction analyses were carried out as described (23, 24, 28, 40) .
Apoptosis Assays-293 cells were transfected with 0.1 g of pCMV-␤-galactosidase plasmid and various amounts of indicated plasmids. ␤-Galactosidase co-transfection assays for determination of cell death were performed as described (23, 24, 28, 40) . Transfected cells were stained with X-gal as described previously (41) . The number of blue cells from four viewing fields in one well of a 35-mm dish was determined by counting under a microscope. The average number from one representative experiment in which each transfection was done in duplicate is shown.
Solid-Phase Kinase Assays-Cytokine-treated or -transfected cells were lysed with 600 l of ice-cold lysis buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10 g/ml aprotinin, 10 g/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 10 mM NaF, 2 mM Na 3 VO 4 , and 1 mM dithiothreitol). The lysate was mixed with 15 l of 1:1 slurry of GST-c-Jun-Sepharose beads, and the mixture was incubated at 4°C for 1 h. The beads were then washed twice with lysis buffer and once with kinase assay buffer (20 mM Hepes, pH 7.5, 10 mM ␤-glycerophosphate, 10 mM p-nitrophenylphosphate, 10 mM MgCl 2 , 1 mM dithiothreitol, 50 M Na 3 VO 4 ). The washed beads were resuspended in 30 l of kinase assay buffer containing 1 l of [␥-
32 P]ATP (10 Ci/L, 1 Ci ϭ 37 GBq) and incubated at 30°C for 30 min. The reaction was terminated by the addition of 30 l of 2 ϫ Laemmli sample buffer and boiled for 5 min. The samples were fractionated by SDS-polyacrylamide gel electrophoresis. The gels were washed in fixing buffer (10% acetic acid, 30% methanol) three times, each for 10 min, and then dried. Autoradiography was performed for 5-30 min. Fold induction of JNK kinase activity was determined by phosphoimaging analysis.
Screening of TRAIL-resistant Cells--HeLa or MCF7 cells (5 ϫ 10 5 ) were treated with 200 ng/ml recombinant TRAIL for 24 h. Treated cells were switched to new medium containing 200 ng/ml TRAIL for additional 24 h. Surviving cells were then amplified and designated as HeLa-TL-R and MCF7-TL-R, respectively.
RESULTS

Activation of NF-B by TRAIL Receptors Is Mediated through a TRAF2-NIK-IKK␣/␤-dependent Signaling
Cascade-Although several studies indicated that TRAIL could induce NF-B activation (8, 10, 21) , one group reported results contrary to this (6) . To determine whether TRAIL could activate NF-B, we transfected 293 cells with a NF-B-luciferase reporter construct and performed luciferase reporter gene assays. As shown in Fig. 1 , treatment with recombinant soluble TRAIL induced NF-B activity. In this experiment, TRAIL was less potent than TNF in activating NF-B (Fig. 1) . To determine the relative contributions of various TRAIL receptors to TRAILinduced NF-B activation, we compared the effects of overexpression of individual TRAIL receptors on NF-B activity in reporter gene assays. As shown in Fig. 2 , TRAIL-R1, TRAIL-R2, and TRAIL-R4 all activated NF-B. TRAIL-R1 was found to be more potent than TRAIL-R2 and TRAIL-R4 in activating NF-B in this experiment, at least partially because of its higher expression level than TRAIL-R2 and TRAIL-R4 (Fig. 2) .
Because TRAIL receptors have similar biological effects as TNF receptors, we tested whether the cytoplasmic proteins involved in TNF receptor signaling, including TRADD, TRAF2, NIK, MEKK1, IKK␣, and IKK␤, also participate in TRAIL receptor signaling. To do this, we determined whether their dominant negative mutants could block TRAIL receptor-mediated NF-B activation in reporter gene assays. TRADD(296S), a TRADD dominant negative mutant that inhibits TNF-R1-mediated NF-B activation (42) (Fig. 2D) , did not block TRAIL-R1-, TRAIL-R2-, and TRAIL-R4-induced NF-B activation (Fig.  2) , suggesting that TRADD is not involved in TRAIL receptormediated NF-B activation pathways. Consistent with this observation, we failed to detect an interaction between TRADD and TRAIL-R1, TRAIL-R2, or TRAIL-R4 in co-transfection and co-immunoprecipitation experiments (data not shown). Interestingly, overexpression of TRADD(296S) potentiated TRAIL receptor-induced NF-B activation (Fig. 2) .
TRAF2-(87-501), a TRAF2 deletion mutant that has been shown to block TNF-R2-induced NF-B activation (43) , potently inhibited TRAIL-R1-, TRAIL-R2-, and TRAIL-R4-induced NF-B activation (Fig. 2) . Consistent with previous reports (24, 43) , TRAF2-(87-501) only weakly inhibited NF-B activation by overexpression of TNF-R1 (Fig. 2D ) but potently inhibited NF-B activation by TNF ligation of endogenous TNF-R1 in 293 cells. 2 These observations are consistent with earlier reports (24, 43) . The kinase-inactive mutants, NIK(K429A/K430A), IKK␣(K44A), and IKK␤(K44A), which have been shown to block TNF and interleukin 1-induced NF-B activation (28 -34, 44) , blocked TRAIL-R1-, TRAIL-R2-, and TRAIL-R4-induced NF-B activation (Fig. 2) . As a positive control, the kinase inactive NIK, IKK␣, and IKK␤ mutants inhibited TNF-R1-induced NF-B activation. As expected, IB␣(S32A/S36A), an IB␣ mutant that cannot be phosphorylated and degraded and therefore has a constitutive inhibitory effect on NF-B (36, 37), completely inhibited TRAIL-R1-, TRAIL-R2-and TRAIL-4-induced NF-B activation (Fig. 2) .
MEKK1(K1255M), a kinase inactive mutant of MEKK1 (45), did not inhibit TRAIL-R4-induced NF-B activation but partially inhibited TRAIL-R1-and TRAIL-R2-induced NF-B activation (Fig. 3, A, C, and E) . However, as MEKK1(K1255M) inhibited basal NF-B activity (Fig. 3, A, C, and E) , the induction folds of NF-B activation by TRAIL-R1, TRAIL-R2, and TRAIL-R4 were actually higher in the presence of MEKK1-(K1255M), compared with the control transfection with empty vector (Fig. 3, B, D, and F) . MEKK1(K1255M) also did not inhibit TNF-R1-induced NF-B activation (Fig. 3, G and H) , which is consistent with the belief that MEKK1 is not involved in TNF-R1-induced NF-B activation (35) . This mutant, however, could potently inhibit TRAIL-R1-induced JNK activation (see below). These data suggest that MEKK1 is not involved in TRAIL-R1-, TRAIL-R2-, and TRAIL-R4-induced NF-B activation.
TRAIL Receptors Activate JNK through a TRAF2-MEKK1-MKK4-dependent Pathway-Several TNF receptor family members are capable of activating the JNK kinase pathway. To determine whether TRAIL and its receptors have a similar effect, we performed solid-phase kinase assays with GST-c-Jun as a substrate. As shown in Fig. 4A , TRAIL treatment induced JNK activation in 293 cells. Similarly, overexpression of TRAIL-R1, TRAIL-R2, and TRAIL-R4 activated JNK (Fig. 4B ) and was further enhanced by TRAIL treatment. To explore the possible signaling pathways leading to TRAIL receptor-induced JNK activation, we tested whether the dominant negative mutants of TRAF2, NIK, MEKK1, MKK4, and IKK␤ could block TRAIL-R1-induced JNK activation. As shown in Fig. 4C , TRAF2-(87-501), MEKK1(K1255M), and the MKK4 dominant negative mutant MKK4-DN inhibited TRAIL-R1-induced JNK activation, whereas NIK(K429A/K430A) and IKK␤(K44A) had no significant inhibitory effect on TRAIL-R1-induced JNK activation (Fig. 4C) . These data suggest that TRAIL-R1-induced JNK activation is mediated by a TRAF2-MEKK1-MKK4 dependent pathway and is independent of the NIK-IKK␣/␤ cascade.
Because the above data indicated that TRAIL-R1-induced NF-B and JNK activation pathways might bifurcate at TRAF2, we examined whether TRAF2 could directly interact with TRAIL-R1 by co-transfection and co-immunoprecipitation experiments. We found that TRAF2 did not interact with TRAIL-R1, TRAIL-R2, and TRAIL-R4 (data not shown), suggesting that unidentified adapter molecule(s) may link TRAF2 to TRAIL receptors.
FADD Is Involved in TRAIL-R1-and TRAIL-R2-induced Apoptosis Pathway-Previously
, it has been reported that TRAIL-R1 and TRAIL-R2 induce apoptosis through a FADDdependent pathway (8, 21) . In contrast, other reports have suggested that FADD is not involved in TRAIL-R1-and TRAIL-R2-induced apoptosis (6, 7, 10, 23). We screened several human cDNA libraries using the yeast two-hybrid system with TRAIL-R1 intracellular domain as bait. These screenings identified FADD as a protein that specifically interacted with TRAIL-R1 (data not shown). Consistent with the physical interaction, FADD-(80 -205), a dominant negative mutant of FADD that inhibits TNF-R1-induced apoptosis (24), significantly inhibited TRAIL-R1-induced apoptosis in a well established apoptosis assay (23, 24, 28, 40) (Fig. 5A) . These data suggest that FADD is involved in a TRAIL-R1-induced apoptosis pathway. 
TRAIL-R1-induced Apoptosis Is Independent of TRAIL-R1-induced NF-B and JNK Activation Pathways-Because
TRAIL-R1 is capable of inducing apoptosis and NF-B and JNK activation, we tested whether the signaling pathways leading to the three distinct effects of TRAIL-R1 could crosstalk. We transfected 293 cells with an expression vector for TRAIL-R1 together with expression vectors for crmA, TRAF2-(87-501), NIK(K429A/K430A), MEKK1(K1255M), IKK␣(K44A), IKK␤(K44A), or IB␣(S32A/S36A). We found that overexpression of TRAIL-R1 potently induced apoptosis. The caspase inhibitor crmA inhibited TRAIL-R1-induced apoptosis (Fig. 5A) . The mutants TRAF2-(87-501), NIK(K429A/K430A), MEKK1 (K1255M), IKK␣(K44A), IKK␤(K44A), and IB␣(S32A/S36A), which inhibited TRAIL-R1-induced NF-B and/or JNK activation, had no effect on TRAIL-R1-induced apoptosis (Fig. 5A) . These data suggest that TRAIL-R1-induced apoptosis and NF-B and JNK activation pathways are mediated through distinct pathways.
Activation of NF-B Is Not Capable of Protecting Cells from TRAIL-R1-induced
Apoptosis-Although TRAIL induces apoptosis of various cancer cells, some cancer cells and normal cells are resistant to TRAIL-induced apoptosis, even though these cells express TRAIL-R1 and TRAIL-R2 (3). Because TRAIL-R1, TRAIL-R2, and TRAIL-R4 can activate NF-B, one of the possible mechanisms responsible for the resistance of a cell to TRAIL may be because of a dominant effect of NF-B activation, which has been shown to protect cells from TNFinduced apoptosis (18 -20) . In this context, it has been suggested that TRAIL-R4, which can induce NF-B activation but not apoptosis, can protect cells from TRAIL-induced apoptosis (16) . To investigate whether NF-B activation is responsible for TRAIL-R4-mediated protection of cells from TRAIL-induced apoptosis, we tested the effects of overexpression of TRAIL-R4 and up-regulation of NF-B activity on TRAIL-R1-mediated apoptosis. As shown in Fig. 5B , overexpression of TRAIL-R4 did not protect TRAIL-R1-induced apoptosis. Co-transfection of 293 cells with expression vectors for TRAIL-R1 and NIK or IKK␤ greatly increased NF-B activity in comparison to TRAIL-R1 transfection alone (Fig. 5C ). However, up-regulation of NF-B activity by overexpressing NIK and IKK␤ had no protective effect on TRAIL-R1-induced apoptosis (Fig. 5B) . These data suggest that overexpression of TRAIL-R4 and activation of NF-B do not protect cells from TRAIL-R1-induced apoptosis.
Inhibition of NF-B Activation Potentiates TNF-, but Not TRAIL-induced Apoptosis-IB␣(S32A/S36A
) is an IB␣ mutant that has more potent inhibitory effect on NF-B activation than its wild type counterpart (36, 37) . To test whether inhibition of NF-B activation can sensitize cells to TRAIL, we determined the effect of IB␣(S32A/S36A) on TRAIL-induced apoptosis. To do this, we first isolated TRAIL-resistant HeLa and MCF7 cells. In these experiments, 90% of HeLa cells and 30% of MCF7 cells were killed. TRAIL-resistant cells, designated as HeLa-TL-R and MCF7-TL-R, respectively, were then amplified and transfected with expression vectors for IB␣(S32A/S36A) and a ␤-galactosidase reporter gene. Fourteen hours after transfection, the cells were treated with TNF, TRAIL, or left untreated for 10 h and then stained by X-gal. As shown in Fig.  6 , transfection of IB␣(S32A/S36A) sensitized both HeLa-TL-R and MCF7-TL-R cells to TNF-but not TRAIL-induced apoptosis. These data are consistent with the hypothesis that activation of NF-B protects TNF-but not TRAIL-induced apoptosis. DISCUSSION TRAIL stimulation induces three distinct biological effects: apoptosis, NF-B, and JNK activation. These effects of TRAIL are mediated through three signaling receptors, including TRAIL-R1, TRAIL-R2, and TRAIL-R4. In this report, we investigated the mechanisms of downstream signaling by the three mentioned TRAIL receptors.
TNF-R1 is a prototypic member of the TNF receptor family, which activates NF-B through a TRADD-TRAF2/RIP-NIK-IKK␣/␤-dependent signaling cascade (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) . In this study, we found that TRADD did not interact with the TRAIL receptors. A dominant negative mutant of TRADD, which blocks TNF-R1-induced NF-B activation (42) (Fig. 2) , did not inhibit TRAIL-R1-, TRAIL-R2-, and TRAIL-R4-induced NF-B activation. Our results are consistent with the reports that TRAIL-R1 and TRAIL-R2 do not interact with TRADD (6, 7) but contradict certain reports that TRAIL-R1 and TRAIL-R2 interact with TRADD in co-transfection/co-immunoprecipitation experi- figure. 1 g of crmA expression plasmid was added to inhibit cell death. 16 h after transfection, cells were lysed, and JNK activity in the lysate was determined by a solid-phase kinase assay using recombinant GSTc-Jun as a substrate. The relative fold induction in JNK activity was determined by phosphoimaging and is indicated at the bottom of each lane.
ments (8, 21) , and a TRADD deletion mutant inhibits TRAIL-R1 and TRAIL-R2-induced NF-B activation (21) . It should be pointed out that the interaction observed by the later two reports was weak, and their co-immunoprecipitation experiments did not have a nonspecific antibody control (8, 21) . In addition, one group used only the intracellular domains of TRAIL-R1 and TRAIL-R2, but not full-length receptor proteins, in their co-immunoprecipitation experiments (8) . The TRADD deletion mutant used by Chaudhary et al. (21) itself activates NF-B and, therefore, is not strictly a dominant negative mutant. In fact, we found that TRADD(296S), a well characterized dominant negative mutant of TRADD (42), potentiated TRAIL receptor-induced NF-B activation. Currently, the mechanism responsible for this observation is not clear.
In this study, we found that TRAIL-R1-, TRAIL-R2-, and TRAIL-R4-induced NF-B activation was potently inhibited by TRAF2-(87-501), NIK(K429A/K430A), IKK␣(K44A), and IKK␤(K44A), but not by MEKK1(K1255M), suggesting that TRAIL-R1-, TRAIL-R2-, and TRAIL-R4-induced NF-B activation is mediated by a TRAF2-NIK-IKK␣/␤-dependent signaling cascade and is independent of MEKK1.
Our studies indicate that TRAIL-R1, TRAIL-R2, and TRAIL-R4 are also capable of inducing JNK kinase activity (Fig. 4) . TRAIL-R1-induced JNK activation can be inhibited by dominant negative mutants of TRAF2, MEKK1, and MKK4 but not by those of NIK and IKK␤. Therefore, TRAIL-R1-induced JNK activation is mediated by a TRAF2-MEKK1-MKK4 dependent pathway and is independent of the NIK-IKK kinase cascade. These data suggest that TRAIL-R1-induced NF-B and JNK activation pathways bifurcate at TRAF2. Because TRAF2 does not directly interact with TRAIL-R1, TRAIL-R2, and TRAIL-R4, whereas FADD is not involved in TRAIL receptor-mediated NF-B activation pathway, we believe that unidentified adapter proteins other than TRADD and FADD are required for recruiting TRAF2 to TRAIL-R1, TRAIL-R2, and TRAIL-R4 signaling complexes.
In addition to NF-B and JNK activation, TRAIL-R1 can potently induce apoptosis. The pathway leading to TRAIL-R1-induced apoptosis, however, remains controversial. We screened yeast two-hybrid libraries with the intracellular domain of TRAIL-R1 as bait and identified FADD as a protein that specifically interacted with TRAIL-R1. 2 Furthermore, a FADD dominant negative mutant significantly inhibited TRAIL-R1-induced apoptosis in 293 cells (Fig. 5A) . Our data support the hypothesis that FADD is involved in TRAIL-R1-induced apoptosis pathway. Previously, it has been shown that overexpression of TRAIL-R1 can induce apoptosis in FADD(Ϫ/Ϫ) embryonic fibroblasts (22) , suggesting that FADD is dispensable for TRAIL-R1-induced apoptosis. However, these experiments can not exclude the possibility that FADD is required for apoptosis induced by ligation of TRAIL-R1 with TRAIL in untransfected cells. For example, the death domain containing TRAIL-R1, when overexpressed, may artificially interact with other death domain-containing proteins, such as RIP, and therefore induce apoptosis in FADD(Ϫ/Ϫ) cells. Alternatively, a FADD-like molecule, which may have higher affinity with TRAIL-R1, can also transduce the death signal from TRAIL-R1 to the downstream caspase cascades.
In our studies, we also found that TRAF2-(87-501), NIK(K429A/ K430A), IKK␣(K44A), IKK␤(K44A), MEKK1(K1255M), and IB␣(SS/AA), the mutants which blocked TRAIL receptor-induced NF-B and/or JNK activation (Figs. 2 and 4) , did not inhibit TRAIL-R1-induced apoptosis (Fig. 5) . These data suggest that TRAIL-R1 induces apoptosis, NF-B, and JNK activation through distinct pathways.
Previous studies indicate that TRAIL-R4 can protect cells from TRAIL-induced apoptosis. At least two hypotheses have been proposed to explain this observation. First, TRAIL-R4 may function as a decoy receptor for TRAIL-induced apoptosis, for example, by competing with TRAIL-R1 and TRAIL-R2 for TRAIL binding. This hypothesis, however, cannot explain the observations that some TRAIL-sensitive cells express both TRAIL-R3 and TRAIL-R4, whereas some TRAIL resistant cells do not have detectable TRAIL-R3 and TRAIL-R4 (3). Second, TRAIL-R4 may activate a protective signal to inhibit TRAILinduced apoptosis, for example, by activating NF-B. Previously, it has been shown that activation of NF-B can inhibit TNF-induced apoptosis, probably through transcriptional induction of apoptosis inhibitory genes (20) . However, this hypothesis is complicated by the fact that stimulation of TRAIL-R1 and TRAIL-R2 simultaneously activates NF-B and induces apoptosis. One can argue that NF-B activity induced by TRAIL-R1 and TRAIL-2 is too low to antagonize the dominant apoptotic effect induced by TRAIL-R1 and TRAIL-R2. In this study, we found that overexpression of TRAIL-R4 did not protect cells from apoptosis induced by TRAIL-R1. In addition, a dramatic up-regulation of NF-B activity by overexpressing NIK and IKK␤ had no significant effect on TRAIL-R1-induced apoptosis (Fig. 5) . Moreover, inhibition of NF-B activation by an IB␣ mutant, IB␣(S32A/S36A), sensitized cells to TNFbut not TRAIL-induced apoptosis (Fig. 6 ). These data suggest that activation of NF-B is not sufficient for protecting cells from TRAIL-induced apoptosis, and an alternative mechanism other than NF-B activation may account for the protective role of TRAIL-R4 on TRAIL-induced apoptosis.
In conclusion, our data indicate that TRAIL induces apoptosis, NF-B activation, and JNK activation through distinct pathways (Fig. 7) . We also conclude that NF-B activation is not sufficient for protecting cells from TRAIL-induced apoptosis.
